Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Removing Pfizer's Chantix Boxed Warning A One-Off, Committee Says

Executive Summary

Advisory committee says data supports dialing back safety label for the smoking cessation product, but shouldn’t be precedent setting.


Related Content

FDA Makes Rare Call, Removes Boxed Warning From Chantix, Zyban Labels
Chantix's Boxed Warning: Will A Positive Vote Justify A Negative Outcome?
Pfizer's Pitch For Chantix Warning Reduction Focuses On Those With Mental Illness
Was FDA Nit-Picking In Criticism Of Pfizer's EAGLES Trial?
Pfizer's Chantix Warning May Remain As FDA Raises Trial Concerns
Pfizer’s Effort To Remove Chantix Boxed Warning May Backfire
US FDA orders "black box" suicidality warnings and studies for Chantix and Zyban


Related Companies

Related Deals

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts